All episodes
Reflections on the Progress and Promise of Personalzied Medicines
Curing Cancer with Math
How Healthcare Consumer Find and Use Price Information
Why Infectious Disease Represents a National Security Threat
Recent Mumps Outbreaks Raise Question If New Vaccine Is Needed
Proposed Legislation Would Weaken Genetic Privacy Protections
How Biomarkers Can Alter the View of and Approach to Alzheimer’s Disease
The Fight for Personalized Medicine Wages on Many Fronts
Big Pharma and the Growth and Outlook for Orphan Drugs
What the Recent Patent Ruling Means for the Future of Gene-Editing Technology
Weighing What Limits Should Be Put on Gene Editing
Enlisting the Immune System in the War on Cancer
Why Scientists Must Also Be Advocates
Sernova Eyes Range of Disease for Implantable Cell Technology
Stratus Wants to Demonstrate Its Telehealth Fluency
Regeneron Embraces Genetics as Fundamental to Drug Development
Despite FDA Setback, KemPharm Advancing Prodrug Pipeline
Using digital technologies to improve diagnosis and treatment of mental health patients
Biotech in 2016 and the Year Ahead with TheStreet’s Adam Feuerstein
Harnessing Gut Bacteria to Treat Disease
A Look at What’s Ahead for Biopharma in 2017
AMA Wants Docs to Have Seat at mHealth Table
Testing of New HIV Vaccine Carries Hopes of a Breakthrough
Centrexion Takes Aim at Pain with Growing Portfolio of Non-Opioid Therapeutics
Bringing Women into Biotech Boardrooms
Novartis Deal Validates Perlara’s Approach to Rare Disease Drug Discovery
Harvesting the Aquatic Microbiome for New Drugs
How TwoXAR Is Using Big Data to Accelerate Drug Discovery
Developer of innovative catheter for cancer drugs turns to crowdfunding
Harnessing Real World Samples and Data to Speed Biomedical Research
A Rich Pipeline Expected to Drive Industry’s Growth
Harnessing Biology to Transform the Economy
How a Predictive Diagnostic Can Reduce Preterm Births
Building Better Drugs for Psychiatric Disorders by Targeting the Causes
The Role of PBMs in the Controversy over Drug Pricing
Why a Rare Genetic Disease May Shed Light on Normal Aging
Battling Zika and Other Diseases Like It
Chronicling a Trailblazer of the Genomics Age
Great Progress, but Concerns Persist About Cancer Care in America
Improving Healthcare by Addressing the Most Challenging Patients
The Case for Chasing Unpopular Indications
Improving Drug Development through Better Use of Biomarkers
Measuring the Value of Incubators and Accelerators
Enlisting New and Old Tools to Combat Antibiotic Resistance
Advancing Cancer Care with New Diagnostic Tools
A Biotech Reinvents Itself and How to Price Drugs
Using Technology to Modernize Preclinical Development
Can the Biotech Industry Stay on Track through Innovative Pricing
Wall Street Turns Its Eyes to ASCO
Understanding the Disease It Never Was on House
Why the State of Innovation Is Encouraging
Can Market Forces Fix Drug Pricing
Digital Health Device Seeks to Push Beyond Cannabis to Test Food, Air, and Water
Why the Cancer Moonshot Offers a Chance to Rethink Funding Priorities
Medtronic Advances Toward an Artificial Pancreas
Using Real-Time Data to Detect HIV Outbreaks
Why Pharma Needs to Forge New Drug Pricing Models
Gensight Targets Gene Therapy on Diseases that Blind
A Vial Problem: How We Waste $3 Billion of Cancer Drugs a Year
The Havoc-Wreaking Zombies Lurking in Life Sciences Boardrooms
New FDA Chief Faces Challenges
Seeking a Best-in-Class Antibody at Bargain Basement Prices
Pharma Bro, Price Controls, and the Quest to Balance Innovation with Affordability
California’s Stem Cell Agency Plots Its Future
ViaCyte Pursues ”Functional Cure” for Type 1 Diabetes
Building a Better Pain Pill
Project GENIE Hopes to Make Precision Medicine a Reality
FDA Wants Industry to Guard Against Cybersecurity Risks of Medical Devices
Pharma’s Leadership Vacuum and Its Price to the Industry
Permanent R&D Tax Credit a Boost to Life Sciences
Biotech in 2015 and the Year Ahead with TheStreet’s Adam Feuerstein
Trends Shaping the New Health Economy in 2016
Declining R&D Productivity Continues to Plague Big Pharma
Searching for Solutions to Rising Specialty Drug Prices
Biohackers Seek a Faster, Cheaper Path to Insulin
A Scorecard to Improve Drugmakers’ Transparency
Forget the Chemistry Set, Mom, I Want a Bioreactor
Ensuring Biological Tools Benefit the Environment
New SEC Rules Open Crowdfunding to the Masses
Harnessing Biology to Address Global Challenges
Immunotherapies ETF Lets Biotech Investors Bet on Emerging Sector
Biotech Investors Turn Their Eyes to Policy Matters
Why the MedTech Industry Should Worry About Future Innovation
Rare Disease Drug Developer Shows Speed of Business Model
Ensuring Value-Based Care Addresses What Matters to Patients
California, Aid-in-Dying, and What We’ve Learned from Oregon
FDA Guidance on Names for Biologics and Biosimilars and its Implications
Understanding the Cost and Value of Cancer Therapies
Jimmy Carter’s Final Wish: Eradicating Guinea Worm
The Quest for a Pink Viagra
Free Speech Ruling May Force FDA to Rethink Off-Label Marketing
Drugmakers Often Late to Report Serious Side Effects
When Hospital Cause, Rather than Cure, Deadly Infections
Rethinking the Value and Price of Drugs
Harnessing Stem Cells to Test Drug Safety
CrowdMed Enlists the Wisdom of Crowds to Solve Medical Mysteries
Biotech’s Record Performance and Looming Threats
What a Decade of Investment Tells Us about the Health of Biotech
What Activist Investors Can Teach Biotech Companies
ALS Fight Carries Muller from Patient to Biotech CEO